Clinical Research Directory
Browse clinical research sites, groups, and studies.
8 clinical studies listed.
Filters:
Tundra lists 8 Solid Malignancies clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07505771
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.
Gender: All
Ages: 18 Years - Any
Updated: 2026-04-06
1 state
NCT06823167
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Gender: All
Ages: 18 Years - Any
Updated: 2026-03-27
9 states
NCT02537418
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
The purpose of this study is to find the highest dose of durvalumab or of durvalumab with tremelimumab that can be tolerated without causing very severe side effects when receiving standard chemotherapy and to see what effects the study drugs has on this type of cancer. Patients may receive durvalumab alone or in combination with tremelimumab.
Gender: All
Ages: 18 Years - Any
Updated: 2026-03-27
4 states
NCT05006794
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
This is a Phase I open-label, multi-center study of zamzetoclax (formerly GS-9716) tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose of zamzetoclax, and characterize the safety and tolerability of zamzetoclax as monotherapy and in combination with anti-cancer therapies.
Gender: All
Ages: 18 Years - Any
Updated: 2026-01-07
10 states
NCT06725381
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor .
Gender: All
Ages: 18 Years - 75 Years
Updated: 2026-01-07
8 states
NCT06600789
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
Gender: All
Ages: 18 Years - Any
Updated: 2025-11-03
2 states
NCT06933069
Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors
This is a multicenter, open-lable phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor activity of CMAB017 in advanced malignant solid tumors.
Gender: All
Ages: 18 Years - 75 Years
Updated: 2025-09-11
NCT06684028
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
To investigate the biological distribution of a new tracer 68Ga-FAPI-JNU in the primary, metastatic and normal tissues of patients with malignant tumors, and to evaluate the biological distribution of 68GA-FAPI-JNU with standardized uptake values.
Gender: All
Ages: 18 Years - 85 Years
Updated: 2025-01-22
1 state